<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022295</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068802</org_study_id>
    <secondary_id>NOVOGEN-NV06-0024</secondary_id>
    <secondary_id>CCF-4269</secondary_id>
    <secondary_id>NCI-V01-1663</secondary_id>
    <nct_id>NCT00022295</nct_id>
  </id_info>
  <brief_title>Phenoxodiol in Treating Patients With Refractory Solid Tumors</brief_title>
  <official_title>Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kazia Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for cancer cell growth.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who&#xD;
      have refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of phenoxodiol in patients with refractory solid&#xD;
           tumors.&#xD;
&#xD;
        -  Determine the steady-state pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the tumor response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive phenoxodiol IV continuously over days 1-7. Treatment repeats every 14 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of phenoxodiol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idronoxil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor&#xD;
&#xD;
               -  Refractory to standard therapy OR&#xD;
&#xD;
               -  No standard therapy exists&#xD;
&#xD;
          -  No breast cancer&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Known CNS metastases must be previously treated with radiotherapy or surgery and&#xD;
                  stable for at least 4 weeks prior to study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL (9 g/dL for women)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.2 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No contraindication to the insertion of a vascular access device&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent systemic anticancer immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent systemic anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic anticancer hormonal therapy except luteinizing&#xD;
             hormone-releasing hormone agonists or antagonists&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent localized radiotherapy for control of local disease complications allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior antineoplastic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham Kelly, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>MEI Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

